三尖刺血治疗急性脑梗死的真实世界临床研究

注册号:

Registration number:

ITMCTR2025001120

最近更新日期:

Date of Last Refreshed on:

2025-06-06

注册时间:

Date of Registration:

2025-06-06

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

三尖刺血治疗急性脑梗死的真实世界临床研究

Public title:

Real world study on the treatment of acute ischemic stroke with three points bleeding therapy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

三尖刺血治疗急性脑梗死的真实世界临床研究

Scientific title:

Real world study on the treatment of acute ischemic stroke with three points bleeding therapy

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

肖靓宜

研究负责人:

伍大华

Applicant:

Xiao Liangyi

Study leader:

Wu Dahua

申请注册联系人电话:

Applicant telephone:

15874866122

研究负责人电话:

Study leader's telephone:

13508491768

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

900314venin@163.com

研究负责人电子邮件:

Study leader's E-mail:

893049352@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

湖南省长沙市岳麓区麓山路58号湖南省中西医结合医院

研究负责人通讯地址:

湖南省长沙市岳麓区麓山路58号 湖南省中西医结合医院

Applicant address:

No. 58 Lushan Road Yuelu District Changsha City Hunan Hospital of Integrated Traditional Chinese and Western Medicine

Study leader's address:

No. 58 Lushan Road Yuelu District Changsha City Hunan Hospital of Integrated Traditional Chinese and Western Medicine

申请注册联系人邮政编码:

Applicant postcode:

410006

研究负责人邮政编码:

Study leader's postcode:

410006

申请人所在单位:

湖南省中西医结合医院(湖南省中医药研究院附属医院)

Applicant's institution:

Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine (The affiliated hospital of Hunan Academy of Traditional Chinese Medicine)

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

202523

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

湖南省中医药研究院附属医院伦理委员会

Name of the ethic committee:

Ethics Committee of the Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2025/2/12 0:00:00

伦理委员会联系人:

戎宽

Contact Name of the ethic committee:

Rongkuan

伦理委员会联系地址:

湖南省长沙市麓山路58号

Contact Address of the ethic committee:

No. 58 Lushan Road Changsha City Hunan Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

0731-88883760

伦理委员会联系人邮箱:

Contact email of the ethic committee:

87048174@qq.com

研究实施负责(组长)单位:

湖南省中西医结合医院(湖南省中医药研究院附属医院)

Primary sponsor:

Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine (The affiliated hospital of Hunan Academy of Traditional Chinese Medicine)

研究实施负责(组长)单位地址:

湖南省长沙市麓山路58号

Primary sponsor's address:

No. 58 Lushan Road Yuelu District Changsha City Hunan Hospital of Integrated Traditional Chinese and Western Medicine

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

长沙市

市(区县):

岳麓区

Country:

China

Province:

Hunan

City:

Changsha

单位(医院):

湖南省中西医结合医院(湖南省中医药研究院附属医院)

具体地址:

湖南省长沙市麓山路58号

Institution
hospital:

Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine (The affiliated hospital of Hunan Academy of Traditional Chinese Medicine)

Address:

No. 58 Lushan Road Yuelu District Changsha City Hunan Hospital of Integrated Traditional Chinese and Western Medicine

经费或物资来源:

国家中医药管理局循证能力提升项目

Source(s) of funding:

National Administration of Traditional Chinese Medicine Evidence-based Capacity Improvement Project

研究疾病:

急性脑梗死

研究疾病代码:

Target disease:

Acute ischemic stroke

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

非随机对照试验

Non randomized control

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

1.评价三尖刺血治疗急性脑梗死的临床疗效; 2.观察三尖刺血治疗急性脑梗死的安全性。

Objectives of Study:

1.To evaluate the clinical efficacy of three points bleeding therapy in the treatment of acute ischemic stroke; 2.Observe the safety of three points bleeding therapy of acute ischemic stroke.

药物成份或治疗方案详述:

三尖刺血具体操作:患者取合理体位,暴露施针部位,刺血前操作者在腧穴部位或其周围用推、揉、挤、捊等方法,使血液集聚于穴位部,再用75%乙醇对穴位进行消毒,使用三棱针快速直刺入穴位0.1-0.2cm,立即出针,使之出血0.1-0.2ml。每日1次,7天为1个疗程。

Description for medicine or protocol of treatment in detail:

Specific operations for tricuspid stabbing blood: The patient is in a reasonable position the acupuncture site is exposed before bloodletting the operator causes blood to gather at the acupoint by pushing kneading squeezing etc. on or around the acupoint then disinfecting the acupoint with 75% ethanol using a three-sided needle to quickly and directly Pierce the acupoint 0.1-0.2cm immediately remove the needle to make blood bleed 0.1-0.2ml If the amount of bleeding is insufficient squeeze the bleeding after acupuncture. Take once a day for 7 days as one course of treatment.

纳入标准:

1.符合急性脑梗死的诊断(参照《中国急性缺血性卒中诊治指南2023》制定的急性脑梗死诊断标准:a.急性起病;b.局灶神经功能缺损,少数为全面神经功能缺损;c.影像学出现责任病灶或症状/体征持续24h以上;d.排除非血管性病因;e.脑CT/MRI排除脑出血); 2.急性发病7天以内; 3.18岁≤年龄,性别不限; 4.NIHSS≥4分; 5.志愿受试,患者或其直系亲属能够并愿意签署知情同意书。

Inclusion criteria

1. Meet the diagnosis of AIS(refer to the diagnostic criteria for AIS formulated in the "Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023": a. Acute onset b. Defects in the local kitchen nerve function with a few cases being generalized neurological deficits; c. The imaging shows the responsible lesion or symptoms/signs for more than 24 hours; d. Rule out non-vascular causes; e. Brain CT/MRI to rule out cerebral hemorrhage; 2. Within 7 days of acute onset; 3.18 years old or younger gender not limited; 4.NIHSS≥4 points; 5. Voluntary participation: The patient or their immediate family members can and are willing to sign the informed consent form.

排除标准:

1.短暂性脑缺血发作或者由脑肿瘤、脑外伤、心源性栓塞等引起脑栓塞者; 2.入组前接受过其他血管开通治疗方法者,如:动脉溶栓、血管内取栓、血管成形支架术等; 3.入组前接受过溶栓治疗者,包括重组组织型纤溶酶原激活剂、尿激酶、替奈普酶等,或替罗非班等静脉抗血小板药物; 4.存在严重凝血障碍、系统性出血病史(包括血小板计数<100×109/L,或者口服抗凝剂(华法林)且INR>1.7或PT>15s); 5.合并有心血管、肝、肾和造血系统等严重原发性疾病、精神病患者(包括成瘾和药物使用障碍、分离性障碍和精神分裂症); 6.妊娠、哺乳期或近期有生育计划的患者。

Exclusion criteria:

1. Transient ischemic attack or cerebral embolism caused by brain tumor brain trauma cardiogenic embolism etc.; 2. Patients who had received other vascular opening treatments before enrollment such as intra-arterial thrombolysis endovascular thrombectomy angioplasty and stenting etc. 3. Patients who received thrombolytic therapy before enrollment including recombinant tissue plasminogen activator urokinase tenecteplase etc. or intravenous antiplatelet drugs such as tirofiban; (4) a history of severe coagulopathy systemic bleeding (including platelet count <100×109/L or oral anticoagulant (warfarin) with INR>1.7 or PT>15s); 5. Patients with serious primary diseases of cardiovascular hepatic renal and hematopoietic systems and psychiatric disorders (including addiction and drug use disorders dissociative disorders and schizophrenia); 6. Patients who are pregnant lactating or have recent plans to have children.

研究实施时间:

Study execute time:

From 2025-06-16

To      2027-12-31

征募观察对象时间:

Recruiting time:

From 2025-06-20

To      2027-12-31

干预措施:

Interventions:

组别:

对照组

样本量:

96

Group:

control group

Sample size:

干预措施:

常规治疗

干预措施代码:

Intervention:

conventional therapy

Intervention code:

组别:

试验组

样本量:

96

Group:

Treatment group

Sample size:

干预措施:

三尖刺血联合常规治疗

干预措施代码:

Intervention:

Three points bleeding therapy combined with conventional therapy

Intervention code:

样本总量 Total sample size : 192

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

湖南

市(区县):

岳阳市

Country:

China

Province:

Hunan

City:

Yueyang

单位(医院):

湖南省第三人民医院

单位级别:

省级

Institution/hospital:

Hunan Provincial Third People's Hospital

Level of the institution:

Provincial level

国家:

中国

省(直辖市):

湖南

市(区县):

长沙市

Country:

China

Province:

Hunan

City:

Changsha

单位(医院):

长沙市中医医院(长沙市第八医院)

单位级别:

市级

Institution/hospital:

Changsha Hospital of Traditional Chinese Medicine (Changsha Eighth Hospital)

Level of the institution:

City level

国家:

中国

省(直辖市):

湖南

市(区县):

长沙市

Country:

China

Province:

Hunan

City:

Changsha

单位(医院):

湖南省中西医结合医院(湖南省中医药研究院附属医院)

单位级别:

省级

Institution/hospital:

Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine (The affiliated hospital of Hunan Academy of Traditional Chinese Medicine)

Level of the institution:

Province-level

国家:

中国

省(直辖市):

湖南

市(区县):

怀化市新晃县

Country:

China

Province:

Hunan

City:

Xinhuang County Huaihua City

单位(医院):

新晃县中医院

单位级别:

县级

Institution/hospital:

Xinhuang County Hospital of Traditional Chinese Medicine

Level of the institution:

County-level

国家:

中国

省(直辖市):

湖南

市(区县):

长沙市

Country:

China

Province:

Hunan

City:

Changsha

单位(医院):

怀化市中医医院

单位级别:

市级

Institution/hospital:

Huaihua Hospital of Traditional Chinese Medicine

Level of the institution:

City level

测量指标:

Outcomes:

指标中文名:

良好结局患者比例

指标类型:

次要指标

Outcome:

The proportion of patients with good outcomes

Type:

Secondary indicator

测量时间点:

第90±3天

测量方法:

Rankin评分(0-2)例数/组别例数×100%

Measure time point of outcome:

Day 90±3

Measure method:

The number of cases with Rankin score (0-2)/the number of cases in each group×100%

指标中文名:

格拉斯哥昏迷评分

指标类型:

次要指标

Outcome:

Glasgow Coma Scale

Type:

Secondary indicator

测量时间点:

第14±3天

测量方法:

GCS评分表

Measure time point of outcome:

Day 14±3

Measure method:

GCS

指标中文名:

美国国立卫生院卒中量表评分

指标类型:

主要指标

Outcome:

National Institutes of Health Stroke Scale score

Type:

Primary indicator

测量时间点:

第14±3天

测量方法:

NIHSS评分表

Measure time point of outcome:

Day 14±3

Measure method:

NIHSS

指标中文名:

美国国立卫生院卒中量表评分

指标类型:

次要指标

Outcome:

National Institutes of Health Stroke Scale score

Type:

Secondary indicator

测量时间点:

第30±3天

测量方法:

NIHSS评分表

Measure time point of outcome:

Day 30±3

Measure method:

NIHSS

指标中文名:

改良Barthel指数

指标类型:

次要指标

Outcome:

Modified Barthel Index

Type:

Secondary indicator

测量时间点:

第14、30、90±3天

测量方法:

MBI评分表

Measure time point of outcome:

Day 14、30、90±3

Measure method:

MBI

指标中文名:

全因死亡率

指标类型:

次要指标

Outcome:

All-cause mortality rate

Type:

Secondary indicator

测量时间点:

第90±3天

测量方法:

全因死亡因数/各组总人数*100%

Measure time point of outcome:

Day 90±3

Measure method:

All-cause mortality factor/Total number of people in each group *100%

指标中文名:

卒中复发率

指标类型:

次要指标

Outcome:

Stroke recurrence rate

Type:

Secondary indicator

测量时间点:

第90±3天

测量方法:

卒中复发人数/各组总人数*100%

Measure time point of outcome:

Day 90±3

Measure method:

The number of recurrent stroke patients/the total number of patients in each group*100%

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它

说明

-

Fate of sample 

Others

Note:

-

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 100
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

本项目为真实世界临床研究,为非随机对照试验,根据患者意愿进行分组,愿意采用三尖刺血法治疗者归为试验组,不愿意采用三尖刺血法治疗者归为对照组。

Randomization Procedure (please state who generates the random number sequence and by what method):

This project is a real-world clinical study and a non-randomized controlled trial. Patients are grouped according to their wishes. Those willing to be treated with the tricuspid puncture method are classified as the experimental group while those unwilling to be treated with the tricuspid puncture method are classified as the control group.

盲法:

不涉及

Blinding:

uninvolved

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究结束后6个月或者在相关研究论文正式发表后的30天在EDC平台共享数据,网址:http://1-dao.net:13579/Login/Cliniclndex

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The data were shared on the EDC platform 6 months after the end of the study or 30 days after the official publication of the relevant research paper

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表(CRF)和电子数据采集和管理系统(EDC)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form (CRF) and Electronic Data Capture (EDC) system

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统